Webinar Date/Time: Fri, Nov 3, 2023 2:00 PM EDT
Watch as we unveil the future of viral vector manufacturing with Resilience's Marlborough, MA site. Join us to explore cutting-edge capabilities, single-use technologies, and streamlined supply chains in viral vector production.
Register Free: https://www.biopharminternational.com/bp_w/innovation-showcase
Join us for an informative webcast with industry experts as they address critical challenges in viral vector manufacturing that Resilience's Marlborough, MA site was built to overcome. Situated in one of the fastest-growing life sciences hub and engineered to advance the field of viral vectors and gene therapy, this webinar will introduce the site’s innovative and efficient design. Don’t miss this opportunity to hear from key leaders in the viral vector and gene therapy manufacturing space.
Key Learning Objectives:
Gain insights into the versatile capabilities of the Marlborough Site and Resilience Gene Therapy Network, including multi-product support and flexible manufacturing suites, facilitating seamless transitions from clinical to commercial projects.
Explore new technologies and contamination control measures that drive efficiency and quality in viral vector manufacturing.
Understand the site’s end-to-end capabilities, spanning from cell bank to drug product fill, and how they streamline the supply chain for greater transparency and productivity.
Who Should Attend:
External manufacturing and strategic sourcing leaders, biopharmaceutical executives, manufacturing leaders, quality assurance professionals, and researchers in the field of advanced therapy manufacturing
John Kerwin, PhD
Technical Head of Gene Therapy Franchise
John Kerwin, PhD is the Technical Head of the Gene Therapy Franchise at Resilience. He is responsible for genome engineering, process and analytical development for viral vectors. He previously led Gene Therapy Manufacturing Sciences for Biogen where he was responsible for late-stage process development and validation of ocular and CNS-directed, AAV-based gene therapies. Prior, he built and directed a viral vector and therapeutic protein core facility at the University of Maryland and was a process development engineer at AERAS Global TB Vaccine Foundation developing viral vector-based and live vaccines. John holds a PhD in Chemical Engineering from the University of Maryland-College Park.
Head of Quality-Marlborough
Malou Jacinto leads the Quality functions at the Resilience Marlborough facility. She has over 25 years of experience in biotech industry supporting Manufacturing and Quality Assurance. Malou has experience in new facility start-ups, facility debottlenecking-redesign and facility qualification. She spent over 20 years of her career at Genentech in Drug Product and Drug Substance Manufacturing and Quality Assurance for both Clinical and Commercial facilities. Malou obtained her Bachelor of Science in Chemistry from University of Santo Tomas, Manila, Philippines.
Head of Manufacturing - Marlborough
Shawn Fitzpatrick, Head of Manufacturing at Resilience's Marlborough site, has over 25 years of experience in Biotechnology. His career spans prominent roles at TKT, Shire, Takeda, and Wuxi Biologics, specializing in facility start-ups and commercial launches. Beyond his industry expertise, he serves as a Board Member at the Just-a-Start Corporation, a non-profit championing equity through stable housing and biotechnology education programs.
Head of Technology
Marion Glenn is the Head of Technology for the Resilience Marlborough facility, encompassing the Manufacturing Sciences and Technology, Validation and Process Automation functions. Marion is a seasoned biotechnology engineer and leader with over 18 years of experience in the field. She started her career at Genentech, California, later acquired by the Roche Group. She received her Master of Sciences degree in biochemical engineering from the Engineer School of Marseille, FRANCE. Over her 15 years at Roche-Genentech Marion has made key contributions within Biologics process development, external and internal manufacturing process transfers across the world.
Executive Director of Gene Therapy Commercial Development
Tarran Pierfelice is a stem cell biologist by training who is currently the Executive Director of Gene Therapy Commercial Development at Resilience. Dr. Pierfelice has more than a decade of gene therapy process development and manufacturing experience spanning business development and commercial operational roles both at CDMOs and cell and gene therapeutics companies. She was the Director of Business Development at Paragon Bioservices, where she was heavily involved in developing the company’s commercial strategy to drive organic growth to position the company for its sale to Catalent. After completing her MBA, Dr. Pierfelice worked at Editas Medicine leading its cell therapy pipeline and CMC strategy business development efforts. Dr. Pierfelice received a BS in Molecular Biology from Florida Institute of Technology, a PhD in Cellular and Molecular Medicine from Johns Hopkins University School of Medicine, and MBA from Harvard Business School.